Thompson Siegel & Walmsley LLC Makes New $1.95 Million Investment in BioHarvest Sciences Inc. $BHST

Thompson Siegel & Walmsley LLC acquired a new position in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 374,717 shares of the company’s stock, valued at approximately $1,945,000.

Separately, Geode Capital Management LLC acquired a new stake in shares of BioHarvest Sciences during the 4th quarter worth about $61,000.

Analysts Set New Price Targets

BHST has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. Roth Mkm initiated coverage on BioHarvest Sciences in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BioHarvest Sciences currently has a consensus rating of “Hold” and an average price target of $10.00.

BioHarvest Sciences Stock Performance

Shares of BioHarvest Sciences stock opened at $3.62 on Wednesday. The business has a 50-day moving average of $4.16 and a 200 day moving average of $4.89. BioHarvest Sciences Inc. has a 12 month low of $3.57 and a 12 month high of $12.80. The stock has a market capitalization of $71.01 million, a price-to-earnings ratio of -6.14 and a beta of 0.70. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.96 and a quick ratio of 2.44.

BioHarvest Sciences (NASDAQ:BHST) last announced its earnings results on Thursday, May 14th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. BioHarvest Sciences had a negative return on equity of 76.03% and a negative net margin of 32.54%.The company had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $8.50 million. As a group, sell-side analysts forecast that BioHarvest Sciences Inc. will post -0.45 earnings per share for the current year.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.